Radiation Oncology

Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.

Brandon R. Mancini, MD, MBA, FACRO, discussed results from a phase 1/2a trial that evaluated [212Pb]VMT-α-NET in patients with advanced NETs.

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT followed by maintenance pembrolizumab.

Results from the ShorTrip trial found that SCRT plus chemotherapy regimens showed promising efficacy for patients with locally advanced rectal cancer.

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.

A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.

Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.

The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.

Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.

Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.

The 1.5T Elekta Unity MR-Linac demonstrated lower rates of erectile dysfunction with neurovascular sparing vs without in patients with intermediate-risk prostate cancer.

Findings may establish a framework for assisting patient counselling and optimizing therapy selection for those undergoing radical cystectomy.

Ten-fraction image-guided hypofractionated radiation therapy could be a feasible treatment option for portal vein tumor thrombosis in patients with HCC.

SBRT demonstrated positive 3-year outcomes as a treatment in patients with early-stage HCC based on results from the phase 2 STRSPH trial.

A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.

Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.

Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.

Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.